PEOPLE - Baxter makes appointment:
This article was originally published in Clinica
The president of US company Baxter, Harry Jansen Kraemer, has been named as its CEO, effective December 31 1998. He will replace Vernon Loucks who will remain as chairman of Baxter's board of directors. William Kilgallon has been promoted to director of global marketing, peritoneal dialysis solutions, for Baxter Healthcare. He was previously director of European marketing of PD solutions.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.